Lung Cancer: Page 2

Guardant Health highlights clinical results at IASLC
A study that used Guardant's GuardantInform database analyzed information from more than 2,000 patients with any EGFR mutation who had undergone osimertinib therapy, as well as outcomes from this therapy up to five years after it began. It showed a 12.5% incidence of the mutation in lung cancer patients unlikely to respond to the treatment, the company said.
August 7, 2022
2020 06 01 18 51 2022 Cancer Lung 400
Foundation Medicine highlights lung cancer study results
The findings are from the Prospective Clinicogenomic (PCG) study and were published August 5 in the Journal of Thoracic Oncology Clinical and Research Reports.
August 7, 2022
2021 11 10 18 26 8156 Science Genome Sequence Dna Map 400
Biodesix touts VeriStrat test results
The blood-based test was predictive of progression-free survival and overall survival in patients with non-small cell lung cancer with low or negative PD-L1 treated with immune checkpoint inhibitors, the firm said.
July 19, 2022
2019 09 09 20 46 2283 Lung Cancer 400
Veracyte genomic test classifies lung cancer risk in study
In a study published in the journal PLOS One, a group of researchers has clinically confirmed that Veracyte's Percepta Genomic Sequencing Classifier (GSC) can accurately classify lung cancer risk from inconclusive samples taken in a bronchoscopy.
July 19, 2022
2022 04 18 13 42 3384 Dna Genome Gene Targeted 400
Medial EarlySign, Roche partner on lung cancer detection
The goal is to deliver validated clinical machine learning models for lung cancer detection with EarlySign's LungFlag technology. The technology uses a variety of signals, including basic demographic, medical, drug, and routine clinical lab data.
July 7, 2022
2022 01 25 22 49 5402 Lung 3 D 400
Philips adopting proteomics results for patient management
The integration of proteomics results from the blood-based test -- along with the radiologic and patient history data currently used to determine treatment decisions -- can help create diagnostic efficiency for cancer care centers, Philips said.
June 29, 2022
2019 12 05 23 56 4761 Philips Rsna 2018 400
Foundation Medicine gets FDA nod for NSCLC CDx
Rozlytrek is a targeted therapy for the treatment of non-small cell lung cancer (NSCLC) developed by Roche's Genentech.
June 8, 2022
2019 10 09 17 32 0093 Dna Cancer Cell 400
Biodesix obtains Medicare coverage for lung nodule test
According to Biodesix, Nodify CDT measures seven autoantibodies associated with tumor antigens to help providers detect lung cancer across all histologies and stages.
June 6, 2022
2020 04 30 21 13 0442 Medicare Puzzle 400
Foundation Medicine, lung cancer groups partner in screening trial
The trial, named the "LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer" (LEADER), is the fourth study conducted through LCMC and a collaborative effort involving multiple academic study sites and pharmaceutical firms.
June 2, 2022
2022 06 03 17 12 0335 Cancer Lung 3 D Black 400
Lucence promotes lung cancer research at ASCO 2022
In three separate poster presentations, Lucence will share data showing how a total nucleic acid approach combining circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) in one liquid biopsy test could increase actionable molecular information in lung cancer patients, according to the company.
May 31, 2022
2022 01 10 23 10 0651 Lab Test Tube Dna Blood 400
CorePath and Cizzle partner to develop lung cancer test
The companies said they will first focus on offering the proprietary test in the U.S., where lung cancer accounts for 25% of all cancer deaths.
May 25, 2022
2019 09 09 20 46 2283 Lung Cancer 400
Biomarker data improves CT lung cancer screening's bottom line
The findings suggest a way to make CT lung cancer screening not only more useful but also economical when it comes to patient outcomes, wrote a team led by Zixuan Zhao, PhD, of Zhejiang University in Hangzhou, China.
May 23, 2022
2019 09 09 20 46 2283 Lung Cancer 400
Previous Page
Page 2 of 7
Next Page